Literature DB >> 1916501

Weekend treatment with 20 and 40 mg omeprazole: effect on intragastric pH, fasting and postprandial serum gastrin, and serum pepsinogens.

L C Baak1, J B Jansen, I Biemond, C B Lamers.   

Abstract

Weekend treatment with 20 mg omeprazole reduces ulcer relapse rates but the results may improve with a higher dose regimen. We have evaluated three day weekend treatment with 20 and 40 mg doses of omeprazole in eight healthy subjects in a double blind crossover study. Twenty four hour ambulatory intragastric pH and basal and meal stimulated serum gastrin and serum pepsinogens A and C values were studied. The investigations began on the Friday before the third weekend course of omeprazole and were repeated on alternate days, except Sundays, for two weeks. When compared with values before the study, median 24 hour intragastric pH and basal and meal stimulated gastrin concentrations were significantly (p less than 0.01-0.05), but transiently, raised with both doses of omeprazole. Basal pepsinogen A and C values were significantly (p less than 0.01) increased on all study days, but did not return to their pre-study values before the next weekend dose, except for pepsinogen C in subjects treated with 20 mg omeprazole. A dose dependent effect was found for all parameters studied (p less than 0.05). In conclusion, weekend treatment with 20 and 40 mg omeprazole produces pronounced and dose dependent increases in intragastric pH, basal and meal stimulated serum gastrin, and basal serum pepsinogen A and C without inducing prolonged hypoacidity or hypergastrinaemia. Weekend treatment with 40 mg omeprazole merits further study in the prevention of peptic ulcer relapse.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1916501      PMCID: PMC1379032          DOI: 10.1136/gut.32.9.977

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  29 in total

1.  Effect of short-term omeprazole administration on serum pepsinogens in relation to fasting serum gastrin and gastric acid secretion.

Authors:  I Biemond; L F Crobach; J B Jansen; C B Lamers
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Effect of intravenous omeprazole on intragastric pH during intravenous infusion of amino acids.

Authors:  L C Baak; J B Jansen; C B Lamers
Journal:  Dig Dis Sci       Date:  1990-05       Impact factor: 3.199

3.  Effect of repeated, once daily, oral omeprazole on gastric secretion.

Authors:  P Müller; H G Dammann; H Seitz; B Simon
Journal:  Lancet       Date:  1983-01-01       Impact factor: 79.321

4.  Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole.

Authors:  S Lanzon-Miller; R E Pounder; M R Hamilton; S Ball; N A Chronos; F Raymond; M Olausson; C Cederberg
Journal:  Aliment Pharmacol Ther       Date:  1987-06       Impact factor: 8.171

5.  Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man.

Authors:  C W Howden; J A Forrest; J L Reid
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

6.  Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity.

Authors:  B K Sharma; R P Walt; R E Pounder; M D Gomes; E C Wood; L H Logan
Journal:  Gut       Date:  1984-09       Impact factor: 23.059

7.  Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase.

Authors:  E Fellenius; T Berglindh; G Sachs; L Olbe; B Elander; S E Sjöstrand; B Wallmark
Journal:  Nature       Date:  1981-03-12       Impact factor: 49.962

8.  Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.

Authors:  C B Lambers; T Lind; S Moberg; J B Jansen; L Olbe
Journal:  N Engl J Med       Date:  1984-03-22       Impact factor: 91.245

9.  Long-term omeprazole treatment in man: effects on gastric endocrine cell populations.

Authors:  R Lamberts; W Creutzfeldt; F Stöckmann; U Jacubaschke; S Maas; G Brunner
Journal:  Digestion       Date:  1988       Impact factor: 3.216

10.  Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.

Authors:  T Lind; C Cederberg; G Ekenved; U Haglund; L Olbe
Journal:  Gut       Date:  1983-04       Impact factor: 23.059

View more
  6 in total

1.  Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells.

Authors:  T Ohara; T Arakawa
Journal:  Dig Dis Sci       Date:  1999-08       Impact factor: 3.199

2.  Does smoking influence the pharmacokinetics and pharmacodynamics of the H2-receptor antagonist famotidine?

Authors:  L C Baak; S Ganesh; J B Jansen; C B Lamers
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

3.  Gastrointestinal hormones in short bowel syndrome. Peptide YY may be the 'colonic brake' to gastric emptying.

Authors:  J M Nightingale; M A Kamm; J R van der Sijp; M A Ghatei; S R Bloom; J E Lennard-Jones
Journal:  Gut       Date:  1996-08       Impact factor: 23.059

4.  Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer.

Authors:  V Savarino; G S Mela; P Zentilin; P Cutela; M R Mele; D Perilli; A Vassallo; A Zambotti; C Mansi; G Celle
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

5.  Effect of synthetic prostaglandin E2 analog enprostil on omeprazole-induced hypergastrinemia and hyperpepsinogenemia.

Authors:  J L Meijer; L F Crobach; J B Jansen; C B Lamers
Journal:  Dig Dis Sci       Date:  1994-03       Impact factor: 3.199

Review 6.  Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

Authors:  M I Wilde; D McTavish
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.